Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05499715 Not yet recruiting - Clinical trials for Advanced Tumor of Digestive Tract or Urinary System

A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors

Start date: September 30, 2022
Phase: Phase 1
Study type: Interventional

This is an open-lable, single-arm, dose escalation and dose extension phase I clinical study of ScTIL designed to observe and evaluate the safety, the tolerance, the pharmacokinetic characteristics and the effectiveness of ScTIL in the treatment of advanced malignant solid tumors, in order to provide the basis for the future clinical research to explore the best recommended phase II dose (PR2D) and treatment scheme.

NCT ID: NCT05498519 Recruiting - Clinical trials for Advanced Solid Tumor

A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor

Start date: April 15, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label and multicenter study of SY-4798, a highly specific and potent inhibitor of FGFR4, in patients with advanced solid tumor. This study has two phases: dose-escalation phase and dose-expansion phase.

NCT ID: NCT05498051 Not yet recruiting - Clinical trials for Colorectal Neoplasms

Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.

IBIZA-1
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections

NCT ID: NCT05497726 Not yet recruiting - Clinical trials for Colorectal Neoplasms

Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW

IBIZA-2
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

This prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using intravenous administration.

NCT ID: NCT05496972 Recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology

Start date: April 21, 2021
Phase:
Study type: Observational

To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.

NCT ID: NCT05496595 Not yet recruiting - Clinical trials for Advanced or Metastatic Solid Tumors

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Start date: September 2022
Phase: Phase 1
Study type: Interventional

Study DC-6001-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAbs as a monotherapy in patients with advanced or metastatic solid tumors. The study comprises Part A (compound DCBY02) and Part B (compound DCSZ11, not yet active).

NCT ID: NCT05495529 Completed - Neoplasm Metastasis Clinical Trials

Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors

Start date: January 1, 2013
Phase:
Study type: Observational

This study aims to analyse retrospectively the feasibility, the safety, and the efficiency, of biliary or digestive protection with room air interposition for thermal ablation of central liver tumors with high iatrogenic risk. Thermal ablation is a mini-invasive and curative treatement of liver tumors. However, it requires to be carefull about surrunding organs, such as digestive structures or central biliary tree, which can be injured if not insulated. The technique of gas interposition to protect adjacent gut is already known and validated with carbonic gas. Nevertheless, resorption of this gas is very fast, making its use tricky to keep a correct insulation during the whole thermal ablation process. Room air interposition is easy to use and can offer a slow resorption speed. Furthermore no datas are available concerning the use of room air whatever the organ protected, and the protection of central biliary tree whatever the gas used.

NCT ID: NCT05495360 Not yet recruiting - Malnutrition Clinical Trials

Effect of Omega 3 Enriched Oral Nutritional Supplement on Nutritional Status of CRC and NSCLC Patients

OMENS
Start date: October 2022
Phase: N/A
Study type: Interventional

A single arm intervention study examining the effect of an omega 3 enriched oral nutritional supplement on nutritional status of CRC and NSCLC patients

NCT ID: NCT05495308 Completed - Clinical trials for Rectal Cancer Stage III

"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome. Nevertheless, data from multicenter high-volume cohorts with long term follow-up are scarce. This is a multicenter observational study using prospectively collected data from the Spanish Rectal Cancer Project database. The main objective of the study is to update long-term oncologic follow-up of those patients treated for LARC with nCRT and surgery (either TME or subtotal TME; S-TME) who had obtained a pCR. Secondary objective is to analyze demographic, clinical, operative and treatment variables in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths. The results are reported in accordance with the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) Statement for observational studies. All calculations are performed using Stata 13.1 (StataCorp, Texas, USA).

NCT ID: NCT05495295 Recruiting - Metastatic Cancer Clinical Trials

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours

PhAST
Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The PhAST Trial is an adaptive first-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours conceived and designed with the contribution of the Gianni Bonadonna Foundation, a non-profit academic research institution aimed at promoting therapeutic innovation in oncology.. The trial includes two parts, a dose escalation phase which will enroll patients with non-selected tumour types, followed by a cohort expansion phase in selected tumour types.